Abstract
Recent evidence highlights levetiracetam (LEV) as an advantageous treatment of absence epilepsy (AE). Thus, we investigated the effects of this drug in DBA/2J mice, a murine model of AE. Similarly to ethosuximide (200 mg/kg, intraperitoneal, i.p.) and sodium valproate (250 mg/kg, i.p.), two classic antiabsence agents, LEV (50-200 mg/kg, i.p.) reduced the occurrence of spike-and-wave discharges, AE's typical electroencephalographic patterns. Our results confirm LEV's efficacy in AE treatment.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anticonvulsants / administration & dosage
-
Anticonvulsants / pharmacology*
-
Electroencephalography / drug effects*
-
Epilepsy, Absence / drug therapy*
-
Epilepsy, Absence / genetics
-
Epilepsy, Absence / physiopathology
-
Ethosuximide / administration & dosage
-
Ethosuximide / therapeutic use
-
Injections, Intraperitoneal
-
Levetiracetam
-
Male
-
Mice
-
Mice, Inbred DBA
-
Piracetam / administration & dosage
-
Piracetam / analogs & derivatives*
-
Piracetam / pharmacology
-
Valproic Acid / administration & dosage
-
Valproic Acid / therapeutic use
Substances
-
Anticonvulsants
-
Levetiracetam
-
Ethosuximide
-
Valproic Acid
-
Piracetam